Biogen
NEWS
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
Biogen and others are seeing the value in, particularly, non-prescription digital therapeutics, as complementary companion therapies to disease-modifying drugs.
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer’s disease.
Ionis announced that the FDA has accepted its NDA for tofersen for SOD1-ALS. The application has been given the priority review designation and an action date of January 25, 2023.
The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with.
The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors to favor its multiple sclerosis drugs over those of its competitors.
At Biogen’s quarterly conference call, outgoing CEO Michel Vounatsos emphasized a strong balance sheet and 10 exciting late-stage programs. The company also raised its 2022 guidance.
The Bay State, home to the busy bio-hub Genetown, is experiencing some growing pains. Companies like Biogen and Eisai (H3 Biomedicine) are reducing their headcount.
Eisai and Biogen’s BLA for lecanemab for Alzheimer’s disease received FDA Priority Review with a target action date of January 6, 2023, while Roche’s lymphoma drug scored the same designation.
JOBS
IN THE PRESS